Targeting Neuroinflammation in Spinal Cord Injury: From Inflammatory Mechanisms to Pharmacological Interventions
核心洞察
Spinal cord injury (搜索) triggers a secondary neuroinflammatory cascade driven by microglial activation, immune infiltration, and sustained pro-inflammatory mediator release that worsens tissue damage and impedes recovery.
The balance between pro-inflammatory (M1) and reparative (M2) microglia/macrophage phenotypes is a critical determinant of injury outcome, with NF-κB (搜索), NLRP3 inflammasome (搜索), TLR4 (搜索), and the CCL2/CCR2 axis (搜索) emerging as promising drug targets.
Despite encouraging preclinical advances, effective clinical translation of anti-neuroinflammatory therapies for SCI remains limited, underscoring a persistent unmet medical need.
Spinal cord injury (搜索) (SCI) triggers a devastating secondary neuroinflammatory cascade—driven by microglial activation, immune infiltration, and sustained pro-inflammatory mediator release—that exacerbates tissue damage and impedes neurological recovery. This inflammatory response, rather than the initial mechanical trauma alone, represents a key determinant of long-term functional outcome and a central focus of emerging therapeutic efforts.
The M1/M2 Balance as a Critical Determinant of Outcome
The dynamic balance between pro-inflammatory (M1) and reparative (M2) phenotypes of microglia and macrophages has emerged as a critical determinant of injury outcome. Pharmacological strategies that shift this polarization toward a neuroprotective and repair-promoting state are a central theme of ongoing investigation, reflecting the recognition that the inflammatory microenvironment can either constrain or support recovery.
Key Signaling Pathways as Pharmacological Targets
Several signaling pathways have been identified as promising pharmacological targets for modulating SCI neuroinflammation. These include NF-κB (搜索), the NLRP3 inflammasome (搜索), TLR4 (搜索), and the CCL2/CCR2 axis (搜索), as well as JAK/STAT (搜索) and MAPK pathways. The chemokine and cytokine networks—particularly the CCL2/CCR2 axis—play an important role in shaping the inflammatory microenvironment, and targeting these mediators represents a key avenue for intervention.
Bridging Mechanism and Clinical Translation
Despite encouraging preclinical advances, effective clinical translation of anti-neuroinflammatory therapies for SCI remains limited. A new research initiative aims to bridge mechanistic insights into SCI neuroinflammation with innovative pharmacological interventions, fostering the development of targeted therapies that can ultimately improve functional recovery after SCI.
The initiative invites original research, comprehensive reviews, and perspectives exploring the pharmacological regulation of SCI-induced neuroinflammation from molecular mechanisms to therapeutic translation. Areas of particular interest include the signaling pathways governing microglial and macrophage polarization, the roles of chemokine and cytokine networks in shaping the inflammatory microenvironment, and the integration of multi-omics approaches and bioinformatics to identify new therapeutic targets and biomarkers.
Novel Delivery and Repositioning Strategies
A key focus of the effort is the development of novel drug delivery systems designed to cross the blood-spinal cord barrier and achieve cell-type-selective targeting, alongside biomaterial-based approaches. Drug repositioning strategies are also highlighted as a means to accelerate the path toward clinical application.
By bringing together multidisciplinary contributions—from molecular pharmacology and neurobiology to drug delivery and translational medicine—the initiative seeks to bridge the gap between mechanistic discovery and clinical application, ultimately fostering the development of effective anti-neuroinflammatory therapies that improve outcomes for SCI patients.